Viracept data

AGPH said its pilot Phase II trial of Viracept had produced sufficent data to select one or more doses for use in large-scale pivotal trials to begin next month.

The company said the four-week pilot revealed more profound responses - at least as effective as any other protease inhibitor - as the dose was increased. ...